Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Turk J Ophthalmol ; 53(1): 58-66, 2023 02 24.
Article in English | MEDLINE | ID: covidwho-2261730

ABSTRACT

This study presents the long-term clinical results of Argus II retinal prosthesis implantation in eyes with light perception and projection in 3 patients with end-stage retinitis pigmentosa. No conjunctival erosion, hypotony, or implant displacement was observed during postoperative follow-up. The electrical threshold values were lower in the macular region and higher close to the tack fixation region and peripherally. Optical coherence tomography scans showed fibrosis and retinoschisis formation at the retina-implant interface in two cases. This was attributed to mechanical and electrical effects on the tissue due to the active daily use of the system and the electrodes' proximity to the retina. The patients were able to integrate the system into their daily lives and perform activities that they could not do before. Studies on retinal prostheses for the rehabilitation of hereditary retinal diseases are ongoing, so both social and clinical observations and experiences related to the implant are valuable.


Subject(s)
Retinal Diseases , Visual Prosthesis , Humans , Retina , Conjunctiva , Postoperative Period
2.
Graefes Arch Clin Exp Ophthalmol ; 260(8): 2773-2774, 2022 08.
Article in English | MEDLINE | ID: covidwho-1976812
3.
Nat Commun ; 13(1): 513, 2022 01 26.
Article in English | MEDLINE | ID: covidwho-1915267

ABSTRACT

Loss of photoreceptors in atrophic age-related macular degeneration (AMD) results in severe visual impairment. Since the low-resolution peripheral vision is retained in such conditions, restoration of central vision should not jeopardize the surrounding healthy retina and allow for simultaneous use of the natural and prosthetic sight. This interim report, prespecified in the study protocol, presents the first clinical results with a photovoltaic substitute of the photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic AMD. In this open-label single group feasibility trial (NCT03333954, recruitment completed), five patients with geographic atrophy have been implanted with a wireless 2 x 2 mm-wide 30 µm-thick device, having 378 pixels of 100 µm in size. All 5 patients achieved the primary outcome of the study by demonstrating the prosthetic visual perception in the former scotoma. The four patients with a subretinal placement of the chip demonstrated the secondary outcome: Landolt acuity of 1.17 ± 0.13 pixels, corresponding to the Snellen range of 20/460-20/565. With electronic magnification of up to a factor of 8, patients demonstrated prosthetic acuity in the range of 20/63-20/98. Under room lighting conditions, patients could simultaneously use prosthetic central vision and their remaining peripheral vision in the implanted eye and in the fellow eye.


Subject(s)
Electric Stimulation Therapy/instrumentation , Electric Stimulation Therapy/methods , Geographic Atrophy/therapy , Macular Degeneration/therapy , Vision Disorders/therapy , Visual Perception , Visual Prosthesis , Aged , Aged, 80 and over , Electric Stimulation , Equipment Design , Eyeglasses , Humans , Retina , Treatment Outcome , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL